Year archive

Novo Nordisk — 2026 filings

All 118 regulatory filings released by Novo Nordisk (NOVO) in 2026, sourced directly from the official regulator.

118 Filings

2026 Period

2026 filings (118)

Filing	Released	Lang
FORM 6-K Regulatory Filings	2026-05-27	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-26	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-05-26	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-26	English
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) Regulatory Filings	2026-05-22	English
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) Regulatory Filings	2026-05-22	English
FORM 6-K Regulatory Filings	2026-05-22	English
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class Regulatory Filings	2026-05-22	English
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class Regulatory Filings	2026-05-22	English
FORM SD Regulatory Filings	2026-05-22	English
FORM 6-K Regulatory Filings	2026-05-22	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-18	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-18	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-18	English
FORM 6-K Regulatory Filings	2026-05-18	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-05-13	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-05-12	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-05-12	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-05-06	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-05-05	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-05-05	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-05	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-05-05	Danish
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-04-27	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-04-27	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-27	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-27	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-04-20	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-04-20	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-20	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-20	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-04-20	English
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemogl Regulatory Filings	2026-04-20	English
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemogl Regulatory Filings	2026-04-20	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-04-13	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-13	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-04-13	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-04-13	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-04-10	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-04-07	English
Novo Nordisk A/S – Share repurchase programme Regulatory Filings	2026-04-07	Danish
Novo Nordisk A/S – Share repurchase programme Transaction in Own Shares	2026-04-07	English
Novo Nordisk A/S – Share repurchase programme Transaction in Own Shares	2026-04-07	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-30	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-03-30	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-30	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-30	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-27	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-27	English
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes Regulatory Filings	2026-03-27	English
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes Regulatory Filings	2026-03-27	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-26	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-23	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-03-23	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-23	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-23	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-20	English
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss Regulatory Filings	2026-03-19	English
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss Report Publication Announcement	2026-03-19	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-03-17	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-03-16	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-16	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-16	English
FORM 6-K Regulatory Filings	2026-03-09	English
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-03-09	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-09	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-09	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-03-04	English
FORM 6-K Regulatory Filings	2026-03-02	English
FORM 6-K Regulatory Filings	2026-03-02	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-02	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-02	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-03-02	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-02-23	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-23	Danish
Novo Nordisk A/S - share repurchase programme Regulatory Filings	2026-02-23	Danish
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-23	Danish
FORM 6-K Regulatory Filings	2026-02-23	English
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved Regulatory Filings	2026-02-23	English
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved Regulatory Filings	2026-02-23	English
FORM 6-K Regulatory Filings	2026-02-20	English
FORM 6-K Regulatory Filings	2026-02-17	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-16	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-16	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-16	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-11	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-11	English
6-K Filing Regulatory Filings	2026-02-11	English
6-K - NOVO NORDISK A S (0000353278) (Filer) Regulatory Filings	2026-02-10	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-10	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-10	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-09	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-09	English
Novo Nordisk A/S - share repurchase programme Transaction in Own Shares	2026-02-09	English
6-K Filing Regulatory Filings	2026-02-09	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-05	English
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Director's Dealing	2026-02-05	English
6-K Filing Regulatory Filings	2026-02-05	English
6-K Filing Regulatory Filings	2026-02-05	English
6-K Filing Regulatory Filings	2026-02-05	English
Novo Nordisk initiates 2026 share repurchase programme Transaction in Own Shares	2026-02-04	English
Novo Nordisk initiates 2026 share repurchase programme Transaction in Own Shares	2026-02-04	English
Novo Nordisk has published its annual report for 2025 Report Publication Announcement	2026-02-04	English
Novo Nordisk has published its annual report for 2025 Annual Report (ESEF) FY 2025	2026-02-04	English
Novo Nordisk has published its annual report for 2025 Report Publication Announcement	2026-02-04	English
20-F Filing Annual Report FY 2025	2026-02-04	English
6-K Filing Regulatory Filings	2026-02-04	English
IRANNOTICE Filing Regulatory Filings	2026-02-04	English
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025 Audit Report / Information FY 2025	2026-02-03	English
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025 Earnings Release FY 2025	2026-02-03	English
Novo Nordisk releases 2026 sales and operating profit outlook Earnings Release FY 2025	2026-02-03	English
Novo Nordisk releases 2026 sales and operating profit outlook Earnings Release FY 2025	2026-02-03	English
6-K Filing Regulatory Filings	2026-02-03	English
6-K Filing Regulatory Filings	2026-02-03	English
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial Regulatory Filings	2026-02-02	English
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial Regulatory Filings	2026-02-02	English
FORM 6-K Regulatory Filings	2026-02-02	English
6-K Filing Regulatory Filings	2026-02-02	English

Filings by year

2026 118 filings
2025 119 filings
2024 357 filings
2023 312 filings
2022 285 filings
2021 239 filings
2020 244 filings
2019 293 filings
2018 549 filings
2017 465 filings
2016 479 filings
2015 274 filings
2014 254 filings
2013 295 filings
2012 320 filings
2011 316 filings
2010 296 filings
2009 204 filings
2008 164 filings
2007 21 filings